- Conditions
- HIV Infections, Peripheral Nervous System Diseases, Pain
- Interventions
- Capsaicin Dermal Patch
- Drug
- Lead sponsor
- NeurogesX
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 18,308
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cocaine Dependence, Alcohol Dependence
- Interventions
- VIVITROL (Naltrexone extended-release injectable suspension), Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Body Odor
- Interventions
- NOBO Aqueous Deodorant, Placebo Aqueous Deodorant
- Other
- Lead sponsor
- Kingdom
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- Brensocatib 10 mg, Brensocatib 25 mg, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 1,767 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more
- Conditions
- Ulcerative Colitis
- Interventions
- Methotrexate
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more
- Conditions
- Alzheimer's Disease
- Interventions
- TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 50 Years to 82 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- peficitinib, Placebo, methotrexate
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 16 more
- Conditions
- Flexible Hammertoe, Semi-flexible Hammertoe
- Interventions
- KN3835, Placebo
- Biological · Other
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Corona, California • Encinitas, California + 17 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
- Biological · Other
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
- Conditions
- Alzheimer Disease
- Interventions
- PQ912, Placebo
- Drug · Other
- Lead sponsor
- Vivoryon Therapeutics N.V.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
- Conditions
- HIV-1-infection
- Interventions
- ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- LX3305, LX3305 Placebo, Methotrexate
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Arthroplasty, Replacement, Knee, Total Knee Arthroplasty
- Interventions
- Lidocaine IV, Saline IV
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615;RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
- Conditions
- Asthma
- Interventions
- Ciclesonide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 74
- States / cities
- Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more
- Conditions
- Narcolepsy
- Interventions
- ADX-N05, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 6 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO)
- Drug
- Lead sponsor
- Ridgeback Biotherapeutics, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Northridge, California • Oxnard, California • Yucaipa, California + 7 more
- Conditions
- Acne Vulgaris
- Interventions
- Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 23
- States / cities
- Encino, California • Fremont, California • Los Angeles, California + 20 more
- Conditions
- Heart Failure and Reduced Ejection Fraction
- Interventions
- LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Interventions
- PROCHYMAL®, Placebo
- Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- asimadoline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anesthesia
- Interventions
- One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
- Combination Product · Drug
- Lead sponsor
- Cetylite Industries
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
- Interventions
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more